Moderna, Inc. vs Eli Lilly & Co.
MRNA vs LLY — side-by-side comparison from reported financials. MRNA leads 4, LLY leads 7 of 11 comparable metrics.
Moderna, Inc.
MRNA · Healthcare
$225.15+14.29%Strong
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | MRNA | LLY |
|---|---|---|
| Price | $225.15 | $1 177.20 |
| Market cap | $89.9B | $1.05T |
| Revenue (TTM) | $2.23B | $79.7B |
| Revenue growth | -53.4% | +31.7% |
| Net margin | -141.4% | 33.5% |
| Free cash flow | -$1.24B | $18.2B |
| Net cash (debt) | $5.21B | ($35.2B) |
| 1-year price return | +717.8% | +37.6% |
| P/E | 3.9 | 41.6 |
| P/E vs own history (cheap-side %) | 10% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | -39% | 93% |
| Altman Z-score | 13.40 | 7.10 |
| CV checks passed | 6 of 10 | 11 of 10 |
| Employees | 4,700 | 50,000 |
Full résumé-style profiles: MRNA CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.